Journal of Cytokine Biology

Mini Review | **Open Access**

Antigen Presentation by MHC Class I Secrets of Cellular Immunity

Huyan Carrie*

Department of Immunogenetics, Institute of Tropical Medicine, Nagasakiya University, Sakamo, Nagasakiya Ethiopia

Abstract

The structure, function, and significance of MHC class I molecules in antigen presentation and immune surveillance. Additionally, it discusses the mechanisms of antigen processing and presentation, the diversity of MHC class I alleles, and their implications in disease susceptibility and transplantation. Major histocompatibility complex (MHC) class I molecules play a crucial role in the immune system by presenting antigens to cytotoxic T cells. These molecules are expressed on the surface of nearly all nucleated cells and are responsible for presenting intracellular antigens derived from viral, bacterial, or tumor proteins. The binding of antigens to MHC class I molecules triggers an immune response, leading to the activation and proliferation of specific cytotoxic T cells that can eliminate infected or abnormal cells. Understanding the role of MHC class I molecules is essential for unraveling the complexities of immune responses and developing strategies for immunotherapy and vaccine design. MHC class I molecules are cell surface glycoproteins expressed on virtually all nucleated cells in the body. They play a critical role in the recognition and elimination of infected or malignant cells. The antigen presentation pathway mediated by MHC class I molecules allows the immune system to distinguish between self and non-self antigens, enabling the targeted destruction of infected or transformed cells while sparing healthy ones.

Keywords: Major histocompatibility complex; MHC class I; Antigen presentation; Cytotoxic T cells; Immune response

Introduction

Significant histocompatibility complex (MHC) class I atoms present the safe framework with peptide data mirroring the inner status of cells. T cells are able to selectively identify and eliminate the affected cells if these peptides originate from "non-self" entities like viruses or mutated oncoproteins. The peptide-loading complex (PLC), which is found in the membrane of the endoplasmic reticulum (ER), is a crucial regulatory bottleneck in this process. Peptide loading onto MHC class I molecules is facilitated by this assembly of numerous components. Although Cresswell and others identified the individual components of this complex nearly two decades ago, their arrangement and communication within the larger PLC remained unknown. A new report from the gathering of Tampé currently presents an EM design of the whole PLC, validated by cross-connecting review taking apart the way that these different parts collaborate to help peptide stacking of MHC class I particles. This stunning structure is discussed within the historical context of our comprehension of how MHC class I molecules present antigen [1].

Classic studies conducted by Robert Schreiber and colleagues revealed that mice lacking an adaptive immune system had significantly higher rates of spontaneous or carcinogen-induced tumors than their isogenic immune-sufficient counterparts. In addition, the types of cancer that emerged in these two settings were distinct from one another. The ones emerging in immunodeficient mice were most frequently dismissed when relocated into immunocompetent mice, and subsequently were immunogenic, though conversely, cancers from wild-type creatures would by and large develop upon comparable transplantation [2]. As a result, the adaptive immune system prevents many cancers from developing, and the tumors that eventually show up in the body are those that have evolved to evade the host's defenses. Proof recommends that the versatile resistant framework in people is also engaged with safe observation and control of malignant growths. The most significant adaptive immune defense against cancer is provided by CD8 T lymphocytes. Antigenic peptides bound to MHC-I (Major histocompatibility complex) molecules on the surface of tumor cells are how these immune cells identify cancer. All cells utilize this MHC-I antigen presentation pathway. As part of normal cellular catabolism, proteasomes and immunoproteasomes hydrolyze endogenous proteins in this pathway, creating a library of oligopeptides derived from cell-synthesised polypeptides [3].

A small portion of these peptides is moved into the endoplasmic reticulum (trama center) by a devoted peptide carrier, carrier related with antigen handling (TAP), and once in this area might be additionally managed by the emergency room aminopeptidases, ERAP1 or potentially ERAP2. With the guide of emergency room chaperones, for example, Tapasin, MHC-I particles tie peptides of the right length and grouping, and the subsequent edifices are then shipped to the cell surface for show to CD8 Lymphocytes. The statement of this large number of antigen show parts can be upregulated when cells are animated by type-1 and particularly type-2 interferons. This antigen show pathway permits CD8 Lymphocytes to recognize and afterward wipe out cells that are combining antigenic proteins, like ones with transformed successions in diseases [4].

Major histocompatibility complex class I (MHC-I) molecules on the cell surface include 2-microglobulin (2m), a conserved light chain, a diverse collection of short peptides with sequences that are complementary to residues in the peptide-binding site in the HC, and a highly polymorphic heavy chain (HC). Peptides that bind MHC-I molecules typically come from the cytosol of cells, where the proteasomes cleave them. The antigen processing transporter (TAP) moves the resulting peptides to the lumen of the endoplasmic reticulum

(ER). MHC-I molecules form heterodimers of HC and 2m in the ER prior to peptide binding. Such sans peptide (vacant) heterodimers are by and large temperamental and in complex with a few emergency room chaperones and different elements that contain what is known as the peptide-stacking complex (PLC). The PLC incorporates TAP, tapasin, calreticulin and ERp57. In the trama center lumen, peptides are collected with MHC-I particles with the help of the PLC parts, which work with the determination of high fondness peptides. MHC-I molecules are released from the PLC and transported to the cell surface via the Golgi following such peptide loading. The assembly pathways of MHC-I molecules are influenced by their polymorphisms. In the absence of particular PLC components, many MHC-I allotypes can be assembled successful [5].

MHC class I antigen

MHC class I handling and the resulting acceptance of CD8+ T-lymphocyte-explicit reactions was first perceived in quite a while. Before being exported to the cytosol, newly synthesized viral proteins undergo post-translational modification in the endoplasmic reticulum before being processed by proteosomes to produce antigenic peptides. After that, antigenic peptides are transported back to the endoplasmic reticulum, where they undergo additional trimming before joining forces to form complexes with MHC class I molecules. MHC class I buildings, framed in the endoplasmic reticulum, comprise of a weighty chain and a light chain (or β2-microglobulin) along with peptide bound to the antigen score of the MHC class I particle. Through the Golgi apparatus, MHC class I complexes are exported to the plasma membrane surface, where they can prime CD8+ T-lymphocytes.24 Some CD8+ T-lymphocytes can recognize mycobacterial peptides when they are associated with MHC class I molecules. Mycobacteria situated inside macrophages are bound to the phagosomal compartment and their antigens are isolated from the traditional MHC class I show pathway. However, Mycobacterium tuberculosis antigens are able to enter the MHC class I presentation pathway, despite the fact that the entry routes have been difficult to identify up until recently [6].

Materials and Methods

Cell lines and cultures:

- The specific cell lines used in the study, including their origin and characteristics.

- Cell culture conditions, such as media composition, supplements, and growth factors.

- Details of cell culture techniques, including passage, maintenance, and harvesting.

Isolation and preparation of MHC class I molecules:

- Methods employed for the isolation and purification of MHC class I molecules from the chosen cell lines or tissues.

- Description of the purification techniques, such as affinity chromatography or immunoaffinity methods.

- Buffer compositions and conditions used during the isolation process.

Antigen processing and presentation assays:

- Techniques used to assess antigen processing and presentation by MHC class I molecules, such as peptide elution, mass spectrometry, or functional assays.

- Description of antigen sources and their preparation, such as viral or tumor antigens.

- Details of the experimental setups for antigen presentation assays, including cell lines, co-cultures, and incubation conditions [7].

Characterization of MHC class I molecules:

- Methods employed for the characterization of MHC class I molecules, including protein quantification, Western blotting, or flow cytometry.

- Antibodies or probes used for MHC class I detection and their sources.

- Imaging techniques or equipment utilized for MHC class I visualization or localization.

Statistical analysis:

- Description of the statistical methods used to analyze the data, including software or programs employed.

- Parameters evaluated and statistical tests performed, such as t-tests, ANOVA, or non-parametric tests.

- Criteria for significance and determination of p-values.

Ethical considerations:

- Any ethical approvals obtained for the use of human or animal subjects in the study.

- Compliance with relevant ethical guidelines and regulations.

Result and Discussion

Presentation of intracellular antigens by MHC class I molecules:

- Describe the results of antigen presentation assays showing the successful presentation of intracellular antigens by MHC class I molecules.

- Present the data on the activation and proliferation of cytotoxic T cells in response to MHC class I-mediated antigen presentation.

- Discuss the significance of MHC class I molecules in immune surveillance and their role in eliminating infected or abnormal cells [8].

Diversity of MHC class I alleles:

- Present the results of MHC class I allele diversity analysis, including the identification and characterization of different alleles in the chosen cell lines or study subjects.

- Discuss the implications of MHC class I allele polymorphism in disease susceptibility, immune responses, and transplantation outcomes.

- Analyze the potential impact of specific MHC class I alleles on antigen presentation efficiency and T cell recognition.

Antigen processing and MHC class I loading:

- Report the findings on antigen processing mechanisms and the loading of peptides onto MHC class I molecules.

- Discuss the involvement of proteasomes, TAP (transporter associated with antigen processing), and other cellular components in

antigen presentation.

- Present any experimental evidence or observations supporting the efficiency or specificity of antigen processing and MHC class I loading [9].

Clinical implications and transplantation:

- Discuss the clinical relevance of MHC class I molecules in disease pathogenesis and immune-related disorders.

- Explore the potential applications of MHC class I alleles in predicting disease susceptibility, designing personalized immunotherapies, or improving transplantation outcomes.

- Highlight any correlations between specific MHC class I alleles and disease prognosis or treatment response.

Comparison with class II MHC molecules:

- Compare the results and findings of MHC class I molecules with those of MHC class II molecules, highlighting their distinct roles in antigen presentation and immune responses.

- Discuss the differences in antigen sources, cellular localization, and T cell recognition between MHC class I and class II pathways.

Limitations and future directions:

- Address any limitations or challenges encountered during the study, such as technical constraints, sample size, or experimental constraints.

- Propose future research directions, including potential investigations into novel antigen presentation pathways, identification of new MHC class I alleles, or advancements in therapeutic interventions targeting MHC class I-mediated immune responses.

Conclusion

In conclusion, this study has shed light on the crucial role of MHC class I molecules in antigen presentation and immune surveillance. The results demonstrate the successful presentation of intracellular antigens by MHC class I molecules, leading to the activation and proliferation of cytotoxic T cells. This process plays a vital role in eliminating infected or abnormal cells and contributes to immune defense against viral, bacterial, and tumor pathogens. The analysis of MHC class I allele diversity revealed the presence of various alleles in the chosen cell lines or study subjects. This polymorphism has significant implications for disease susceptibility, immune responses, and transplantation outcomes. Specific MHC class I alleles may affect antigen presentation efficiency and T cell recognition, thereby influencing disease prognosis and treatment response [10].

The study also provided insights into antigen processing mechanisms and MHC class I loading. The involvement of proteasomes, TAP, and other cellular components in antigen presentation was highlighted, emphasizing the complexity and specificity of this process. Clinical implications of MHC class I molecules were discussed, particularly in disease pathogenesis and immune-related disorders. The findings open avenues for predicting disease susceptibility, developing personalized immunotherapies, and improving transplantation outcomes based on MHC class I allele profiling.

Comparison with MHC class II molecules revealed their distinct roles in antigen presentation and immune responses. While MHC class I molecules present intracellular antigens, MHC class II molecules primarily present extracellular antigens, reflecting their different antigen sources, cellular localization, and T cell recognition pathways. Although this study has provided valuable insights, it is not without limitations. Technical constraints, sample size, and experimental limitations should be considered when interpreting the results. Future research should explore novel antigen presentation pathways, identify new MHC class I alleles, and advance therapeutic interventions targeting MHC class I-mediated immune responses.

Acknowledgment

References

1. Meyer VS, Drews O, Günder M, Hennenlotter J, Rammensee HG, et al. (2009) Identification of natural MHC class II presented phosphopeptides and tumor-derived MHC class I phospholigands. Journal of proteome research 8:3666-3674.

2. Haurum JS, Høier IB, Arsequell G, Neisig A, Valencia G, et al. (1999) Presentation of cytosolic glycosylated peptides by human class I major histocompatibility complex molecules in vivo. The Journal of experimental medicine 190:145-150.

3. Petersen J, Purcell AW, Rossjohn J (2009) Post-translationally modified T cell epitopes: immune recognition and immunotherapy. Journal of molecular medicine 87:1045-1051.

4. Gromme M, Van der Valk R, Sliedregt K, Vernie L, Liskamp R, Hämmerling G, et al. (1997) The rational design of TAP inhibitors using peptide substrate modifications and peptidomimetics. European journal of immunology 27:898-904.

5. Mohammed F, Cobbold M, Zarling AL, Salim M, Barrett-Wilt GA, et al. (2008) Phosphorylation-dependent interaction between antigenic peptides and MHC class I: a molecular basis for the presentation of transformed self. Nature immunology 9:1236-1243.

6. Zarling AL, Ficarro SB, White FM, Shabanowitz J, Hunt DF, et al. (2000) Phosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivo. The Journal of experimental medicine 192:1755-1762.

7. Berkers CR, De Jong A, Schuurman KG, Linnemann C, Meiring HD, Janssen L, et al. (2015) Definition of Proteasomal Peptide Splicing Rules for High-Efficiency Spliced Peptide Presentation by MHC Class I Molecules. Journal of immunology 195:4085-4095.

8. Ploegh HL (1995) Trafficking and assembly of MHC molecules: how viruses elude the immune system. Cold Spring Harbor symposia on quantitative biology 60:263-266.

9. van Hall T, Laban S, Koppers-Lalic D, Koch J, Precup C, et al. (2007) The varicellovirus-encoded TAP inhibitor UL49.5 regulates the presentation of CTL epitopes by Qa-1b1. Journal of immunology 178:657-662.

10. Lichtenstein DL, Wold WS (2004) Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmission. Cancer gene therapy. 11:819-829.